Pharmacovigilance

Do GLP-1 Receptor Agonists Increase the Risk of Clinically Recorded Hair Loss Compared With Other Diabetes Drug Classes in 2026?

A 2024 BMJ target-trial emulation using Penn Medicine electronic health records found that GLP-1 receptor agonist initiators had a statistically significant higher incidence of clinically recorded alopecia than users of DPP-4 inhibitors or SGLT-2 inhibitors, with an adjusted hazard ratio of approximately 1.33 versus DPP-4 inhibitors after propensity-score weighting.